Scope and Claims: US Drug Patent 10,966,984
US Patent No. 10,966,984 is directed to a combination treatment method in oncology that pairs:
1) A selective CDK4/6 inhibitor (defined by a specific chemical structure in the claim text you provided), dosed on a tight pre-administration timing window relative to chemotherapy, and
2) A chemotherapeutic agent selected from enumerated lists (varying by dependent claim), for a defined set of cancer types.
At claim level, the invention is not framed as a CDK4/6 inhibitor formulation, dosing, or dosing schedule alone. It is a sequenced regimen: the CDK4/6 inhibitor is administered about 24 hours or less prior to the chemotherapy, with multiple dependent claims tightening that window to about 4 hours or less, and in separate claim paths to about 1/2 hour or less.
Core independent claim structure (Claim 1)
Claim 1 recites:
- Treating a human with cancer
- Administering an effective amount of a selective CDK4/6 inhibitor (structure specified in the claim; or pharmaceutically acceptable salt)
- Administering a chemotherapeutic agent
- Timing: the CDK4/6 inhibitor is administered about 24 hours or less prior to the chemotherapeutic agent
Timing sub-scope (dependent claims)
The timing is the primary “handle” for scope control:
- Claim 2: CDK4/6 inhibitor is administered about 4 hours or less prior to chemotherapy
- Claim 27: CDK4/6 inhibitor is administered about 1/2 hour or less prior to chemotherapy (additional dependent claim tethered to Claim 1)
This creates at least three commercially relevant operational windows:
- ≤24 hours (broadest method claim coverage under Claim 1 baseline)
- ≤4 hours (narrower)
- ≤0.5 hours (narrowest timing carve-in)
Tumor-type sub-scope (dependent claims)
Claim 1 is drafted as “cancer” broadly, then narrows via dependent claims to specific tumor indications:
- Lung cancer (Claim 4)
- Small cell lung cancer (Claim 11)
- Breast cancer (Claim 5)
- Triple negative breast cancer (Claim 12)
- Human papilloma virus (HPV) positive head and neck cancer (Claim 6)
- Cervical cancer (Claim 7)
- Prostate cancer (Claim 8)
- Bladder cancer (Claim 9)
- Colorectal cancer (Claim 10)
A dedicated independent claim exists for one tumor subset:
- Claim 19: method for treating triple negative breast cancer with the same general regimen as Claim 1 but with the timing explicitly recited as 24 hours or less.
Chemotherapy agent sub-scope (dependent claims)
Chemotherapy selection is controlled by dependent claim lists. These lists differ across claim branches:
Claim set tied to Claim 1 (via Claim 3)
Claim 3 enumerates chemotherapeutic agents:
- etoposide
- carboplatin
- gemcitabine
- topotecan
- paclitaxel
- docetaxel
- doxorubicin
- cisplatin
- fluorouracil
(and combinations)
Specific agent dependents include:
- etoposide (Claim 13)
- carboplatin (Claim 14)
- gemcitabine (Claim 15)
- topotecan (Claim 16)
- paclitaxel (Claim 17)
- docetaxel (Claim 18)
- cisplatin (Claim 28) and 5-fluorouracil (Claim 29) are also explicitly recited within the set.
Claim set tied to Claim 19 (via Claim 22)
For triple negative breast cancer, the chemotherapeutic list changes:
- carboplatin
- gemcitabine
- paclitaxel
- doxorubicin
- cyclophosphamide
(and combinations)
With dependents:
- carboplatin (Claim 23)
- gemcitabine (Claim 24)
- paclitaxel (Claim 25)
- doxorubicin (Claim 26)
- cyclophosphamide appears as a selectable chemotherapeutic in Claim 22 and Claim 30.
Net effect: the patent covers a method structure for TNBC that includes a different chemotherapy menu than the general Claim 1/3 branch.
Claim Coverage Map (What the Claims Actually Cover)
1) Regimen logic (unified structure)
All method claims you provided share this regimen template:
- CDK4/6 inhibitor (selective; specific structure)
- given at an effective amount
- before chemotherapy
- with a maximum pre-dose interval of:
- ≤24 hours (main line under Claim 1 and explicitly Claim 19),
- ≤4 hours (Claim 2 and via the TNBC claim family at Claim 20),
- ≤0.5 hours (Claims 21 and 27)
2) Indication coverage (dependent claim funnel)
The indication coverage is broad at Claim 1 level (“cancer”) but becomes explicitly enumerated through dependent claims for:
- Lung (small cell)
- Breast (triple negative)
- HPV+ head and neck
- Cervical
- Prostate
- Bladder
- Colorectal
A practical consequence is that a challenger has to evaluate both:
- whether a specific combination practice falls within the enumerated indication dependents, and
- whether the independent claim’s “cancer” scope is broad enough to be infringed without relying on those dependents.
3) Chemotherapy scope (two different enumerations)
The patent’s scope bifurcates along two chemotherapy enumerations:
- General cancer branch (via Claim 3): includes a wide list including topotecan, cisplatin, and fluorouracil.
- TNBC branch (via Claim 22): restricts to carboplatin, gemcitabine, paclitaxel, doxorubicin, cyclophosphamide.
This matters for freedom-to-operate when choosing the chemotherapy backbone.
Tightest Infringement Windows by Claim Set
Broad method claim window
- ≤24 hours pre-chemo is the baseline:
- Claim 1: “about 24 hours or less”
- Claim 19 (TNBC): “24 hours or less” (same maximum interval expressed without “about” in your provided text)
Intermediate window
- ≤4 hours:
- Claim 2 (general)
- Claim 20 (TNBC)
Fast sequencing window
- ≤0.5 hours:
- Claim 21 (TNBC)
- Claim 27 (general)
Operational reading: if a clinician administers the CDK4/6 inhibitor more than 24 hours before chemotherapy, the timing limitation in the claims you provided is not met. If they administer within 24 hours but not within 4 or 0.5 hours, only the broader timing dependent pathway (≤24) stays in play.
Drafting and Scope Characteristics That Control Validity and Enforcement
1) “Selective CDK4/6 inhibitor” is structure-defined
The claim text indicates the inhibitor is defined by a specific structure (your excerpt includes “of structure:” followed by the structure placeholder). This is significant because:
- It ties infringement to the chemical scope of that structure (and salts).
- It limits “selective CDK4/6 inhibitor” to molecules that fall within that structural definition, not an amorphous functional definition.
2) Timing is the primary differentiator over background combination therapy
Cancer combination regimens with CDK4/6 inhibitors and chemotherapy exist broadly in the art. The claims you provided emphasize the relative sequencing (≤24 hours; and tighter windows). That indicates the patentee’s practical claim strategy is to differentiate from prior art by administration order and pre-dose timing.
3) Dependent claim lists create “chemotherapy menu” fences
The chemotherapy recitations are enumerated lists. This can reduce overbreadth arguments in litigation by providing crisp chemotherapeutic categories rather than “any chemotherapy agent.”
4) Independent claim for TNBC is narrower in claim structure but not in timing maximum
Claim 19 is its own independent claim. It:
- targets triple negative breast cancer and
- retains the ≤24 hours timing requirement.
It then has dependent claims for ≤4 hours and ≤0.5 hours sequencing (Claims 20 and 21).
Patent Landscape for the US 10,966,984: Scope Implications for Competitors
You asked for a “detailed analysis of the scope and claims and patent landscape.” From the information provided, only the claim set can be analyzed with precision. A complete patent landscape would require the complete bibliographic record (filing date, priority, assignee, related family members, and examiner-cited art), which is not included here.
What can be concluded from claim scope alone is the competitive risk shape:
Who is most exposed (based strictly on claim elements provided)
Exposure is highest for companies whose clinical programs:
- use the same structural CDK4/6 inhibitor (or salts) and
- combine it with chemotherapy agents from the claim lists, and
- dose the CDK4/6 inhibitor within 0 to 24 hours before chemotherapy (and potentially within 4 or 0.5 hours).
Where design-around is most plausible in principle (based strictly on claim limitations)
Within the constraints of the claim language you provided, competitors can reduce risk by moving out of claimed limitations in at least one dimension:
- dose the CDK4/6 inhibitor more than 24 hours before chemotherapy (timing)
- select a chemotherapy backbone outside the enumerated lists for the relevant indication path (agent list)
- target indications not covered by the dependent indication claims while still potentially being covered by Claim 1’s “cancer” phrasing (so indication-only design-around may be less reliable for Claim 1 than for the TNBC independent claim)
Because “cancer” at Claim 1 level is broad, indication changes alone are less protective than timing or chemotherapy changes.
Practical “Infringement Trigger” Checklist (Built from the claims you provided)
A regimen is within the literal claim scope if it satisfies:
1) Patient: human with cancer (or TNBC for Claim 19)
2) Drug 1: selective CDK4/6 inhibitor defined by the claimed structure (or salt)
3) Effective amount of CDK4/6 inhibitor
4) Drug 2: chemotherapeutic agent included in the relevant dependent claim list
5) Sequence: CDK4/6 inhibitor administered ≤24 hours before chemotherapy (and dependent claims for ≤4 hours or ≤0.5 hours)
Key Takeaways
- US 10,966,984 covers sequenced combination methods: a structure-defined selective CDK4/6 inhibitor dosed ≤24 hours before chemotherapy, with narrower claim paths at ≤4 hours and ≤0.5 hours.
- Indication scope includes lung (incl. small cell), breast (incl. TNBC), HPV+ head and neck, cervical, prostate, bladder, and colorectal via dependents, with a dedicated TNBC independent claim (Claim 19).
- Chemotherapy scope is enumerated and differs by claim family:
- general branch lists agents including etoposide, topotecan, cisplatin, and fluorouracil
- TNBC branch lists carboplatin, gemcitabine, paclitaxel, doxorubicin, cyclophosphamide.
- The main competitive lever is sequencing. The second lever is chemotherapy backbone selection relative to the enumerated lists.
FAQs
1) Is the patent about using CDK4/6 inhibitors alone?
No. The claims are combination methods requiring CDK4/6 inhibitor + a specified chemotherapy agent with a defined pre-administration timing.
2) What is the maximum timing window the claims require?
The broadest stated maximum is about 24 hours or less prior to chemotherapy (Claim 1 baseline), with dependent claims tightening to about 4 hours or less and about 1/2 hour or less.
3) Does the patent cover triple negative breast cancer separately?
Yes. Claim 19 is an independent TNBC method claim using the same timing maximum (24 hours or less) and has dependent claims for ≤4 hours and ≤0.5 hours sequencing.
4) Are all chemotherapeutics covered?
No. Chemotherapeutic agents are limited to enumerated lists in the dependents. The TNBC family uses a different list than the general cancer branch.
5) What is the most direct design-around based on these claims?
Avoid practicing the claimed sequence (administer CDK4/6 inhibitor more than 24 hours before chemotherapy) and/or use chemotherapeutic agents not included in the applicable enumerated lists.
References
[1] User-provided claim text for US Drug Patent 10,966,984 (Claims 1-30).
